Allakos (NASDAQ:ALLK) Stock Price Up 6.1%

Shares of Allakos Inc. (NASDAQ:ALLK) traded up 6.1% during mid-day trading on Thursday . The stock traded as high as $112.62 and last traded at $111.77. 7,934 shares traded hands during trading, a decline of 96% from the average session volume of 184,998 shares. The stock had previously closed at $105.36.

A number of research firms have recently weighed in on ALLK. Cowen started coverage on shares of Allakos in a research report on Thursday, July 15th. They set an “outperform” rating and a $76.53 price target for the company. Morgan Stanley began coverage on Allakos in a research note on Thursday, August 26th. They set an “equal weight” rating and a $88.00 price objective on the stock. Finally, Zacks Investment Research downgraded Allakos from a “hold” rating to a “sell” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $141.42.

The firm has a 50 day simple moving average of $95.67 and a two-hundred day simple moving average of $95.61. The stock has a market cap of $6.06 billion, a P/E ratio of -29.18 and a beta of 0.79.

Allakos (NASDAQ:ALLK) last issued its quarterly earnings data on Sunday, August 8th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.01). As a group, equities research analysts anticipate that Allakos Inc. will post -4.45 EPS for the current fiscal year.

In other news, Director Steven P. James sold 4,000 shares of the stock in a transaction that occurred on Tuesday, September 28th. The shares were sold at an average price of $108.12, for a total value of $432,480.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 34.45% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. Caption Management LLC boosted its position in shares of Allakos by 252.2% during the 1st quarter. Caption Management LLC now owns 29,236 shares of the company’s stock valued at $3,356,000 after purchasing an additional 20,936 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Allakos by 147.9% during the first quarter. SG Americas Securities LLC now owns 10,281 shares of the company’s stock worth $1,180,000 after buying an additional 6,133 shares in the last quarter. Moneta Group Investment Advisors LLC acquired a new position in Allakos in the first quarter worth approximately $5,115,000. Citigroup Inc. lifted its position in shares of Allakos by 453.1% during the 1st quarter. Citigroup Inc. now owns 38,806 shares of the company’s stock valued at $4,454,000 after acquiring an additional 31,790 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Allakos by 148.4% during the 1st quarter. JPMorgan Chase & Co. now owns 29,465 shares of the company’s stock worth $3,382,000 after acquiring an additional 17,601 shares in the last quarter. Hedge funds and other institutional investors own 82.70% of the company’s stock.

Allakos Company Profile (NASDAQ:ALLK)

Allakos, Inc engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis.

Further Reading: Stocks Increasing Dividends

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.